Further studies using either pharmacological or genetic inhibition of CCL2 and NO demonstrated the role of the Slc4a4 in regulating the CCL2-CCR2 pathway and NO metabolism in the context of BBB recovery after stroke. The gene discussed is SLC4A4; the disease is stroke disorder.